BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26703717)

  • 1. Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.
    Sánchez D; Pelayo R; Medina LA; Vadillo E; Sánchez R; Núñez L; Cesarman-Maus G; Sarmiento-Silva RE
    Viruses; 2015 Dec; 8(1):. PubMed ID: 26703717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newcastle disease virus as an oncolytic agent.
    Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
    Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newcastle disease virus strain AF2240 as an oncolytic virus: A review.
    Kalyanasundram J; Hamid A; Yusoff K; Chia SL
    Acta Trop; 2018 Jul; 183():126-133. PubMed ID: 29626432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newcastle disease virus: a promising agent for tumour immunotherapy.
    Zhao L; Liu H
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
    Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
    BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
    Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
    Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
    Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
    Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NDV-MLS as an Immunotherapeutic Strategy for Breast Cancer: Proof of Concept in Female Companion Dogs with Spontaneous Mammary Cancer.
    Sánchez D; Cesarman-Maus G; Romero L; Sánchez-Verin R; Vail D; Guadarrama M; Pelayo R; Sarmiento-Silva RE; Lizano M
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain.
    Balogh A; Bátor J; Markó L; Németh M; Pap M; Sétáló G; Müller DN; Csatary LK; Szeberényi J
    Virus Res; 2014 Jun; 185():10-22. PubMed ID: 24637408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
    Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
    Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newcastle disease virus LaSota strain induces apoptosis and activates the TNFα/NF-κB pathway in canine mammary carcinoma cells.
    Wang J; Li M; Li M
    Vet Comp Oncol; 2023 Sep; 21(3):520-532. PubMed ID: 37282822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
    Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
    J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic effect of Newcastle disease virus is attributed to interferon regulation in canine mammary cancer cell lines.
    Santos MR; Xavier PLP; Pires PRL; Rochetti AL; Rosim DF; Scagion GP; de Campos Zuccari DAP; Munir M; Ferreira HL; Fukumasu H
    Vet Comp Oncol; 2021 Sep; 19(3):593-601. PubMed ID: 33871162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progress in using Newcastle disease virus for tumor therapy: a review].
    Wu Y; Hao J; Li D
    Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.
    Zamarin D; Palese P
    Future Microbiol; 2012 Mar; 7(3):347-67. PubMed ID: 22393889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model.
    Yurchenko KS; Glushchenko AV; Gulyaeva MA; Bi Y; Chen J; Shi W; Adamenko LS; Shestopalov AM
    Viruses; 2021 Mar; 13(4):. PubMed ID: 33806229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy is involved in recombinant Newcastle disease virus (rL-RVG)-induced cell death of stomach adenocarcinoma cells in vitro.
    Bu XF; Wang MB; Zhang ZJ; Zhao YH; Li M; Yan YL
    Int J Oncol; 2015 Aug; 47(2):679-89. PubMed ID: 26058483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic effect of death: Newcastle disease virus and its antitumor potential.
    Cuadrado-Castano S; Sanchez-Aparicio MT; García-Sastre A; Villar E
    Virus Res; 2015 Nov; 209():56-66. PubMed ID: 26221764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.
    Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
    Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.